Compare Gilead Sciences, Inc. (GILD) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Oxford Lane Capital Corp — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Oxford Lane Capital Corp trades at $9.04 (market cap $881.29M). The key difference: Gilead Sciences, Inc. is far larger — about 185.5× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (26.59%). Which is the better fit depends on your goals.
| GILD | OXLC | |
|---|---|---|
Market Cap | $163.51B | $881.29M |
Sector | Health | Financials |
52-Week High | $155.80 | $20.75 |
52-Week Low | $108.22 | $8.15 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 26.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Oxford Lane Capital Corp. (OXLC) trades at $9.005, down 1.37% on the day, amid a bearish technical signal and severe fundamental deterioration. The stock's price-to-book ratio of 0.85 suggests undervaluation relative to assets, but this is overshadowed by catastrophic earnings misses, a negative return on equity of -39.16%, and a projected revenue collapse into negative territory for 2026, as indicated in recent financial trends.
The outlook is highly risky. While a 50% analyst buy consensus and a high dividend yield present a speculative income opportunity, the core risks are substantial, including unsustainable distributions funded by dilution, rapid net asset value erosion, and significant operational cash outflows, as highlighted in critical Seeking Alpha reports from May 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
